To further evaluate the potential of GSK‐3β as a therapeutic target for AD‐like pathologies and cognitive impairments in ApoE4‐T2DM conditions, we administered intraperitoneally 9‐ING‐41, a specific small‐molecule inhibitor of GSK‐3β [45], into the ApoE4‐T2DM mice (Figure 6a). Here, GSK3B is linked to type 2 diabetes mellitus.